In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
The ENGOT-ov65/KEYNOTE-B96 trial reported small but clinically relevant progression-free survival increments and significantly improved overall survival in platinum-resistant ovarian cancer
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall survival
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
Early studies investigated the potential of genomic profiling, but prospective and comprehensive data are required to support wider implementation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.